TransCode Q3 operating loss widens to $4.95M; cash $8.8M, runway through Q1 2023

Transcode Therapeutics, Inc.

2022-Q3 EPS reported -$0.96

Q3 operating loss $4.95M vs $2.36M in prior year; R&D expense $3.0M, up from $993K.
Cash $8.8M at Sept 30 (down from $20.8M); plus ~$928K SBIR grant; expects to fund only through Q1 2023.
Submitted eIND for Phase 0 trial of lead candidate TTX-MC138; reported preclinical efficacy in pancreatic cancer models.
FDA granted orphan drug designation for TTX-siPDL1 in pancreatic cancer; strategic alliance with MD Anderson announced.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Transcode Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, TransCode Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-118565

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.